The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the generic lanreotide label, and added Drugs@FDA approval records for lanreotide products. 12
What this version reported
Smaller randomized, placebo-controlled trials described in the label support its uses, including a tumor trial in which lanreotide lengthened progression-free survival. The cited label has no boxed warning.↗
Reader guide in this version
Key takeaway
Lanreotide is a lab-made analogue of somatostatin, a hormone that suppresses the release of growth hormone and other hormones. It was first approved in the United States as Somatuline Depot in 2007.1,2 It is FDA-approved for three uses: long-term treatment of acromegaly when surgery or radiation has not worked or is not an option, certain advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.1 In the label’s tumor trial of 204 people, disease progression or death occurred in 31.7% of the lanreotide group and 58.3% of the placebo group.1
At a glance
- What it is
- A somatostatin analogue. The label describes lanreotide as an octapeptide, eight amino acids long, that is thought to act like natural somatostatin.1
- FDA status
- FDA-approved. Drugs@FDA lists Somatuline Depot with an original approval date of August 30, 2007, and later lanreotide applications. The cited label has no boxed warning.1,2,3,4
- Human evidence
- Smaller randomized, placebo-controlled trials described in the label, in acromegaly, neuroendocrine tumors and carcinoid syndrome.1
- Evidence strength
- Smaller controlled human trials
What is lanreotide?
Lanreotide is a lab-made peptide of eight amino acids. The label describes it as an analogue of natural somatostatin.1
Drugs@FDA lists Somatuline Depot, from Ipsen, approved in 2007, and later lanreotide applications approved in 2021 and 2024. The label cited on this page is a generic lanreotide label rather than the Somatuline Depot label.1,2,3,4
How does lanreotide work?
The label states that lanreotide’s mechanism of action is believed to be similar to that of natural somatostatin.1
In acromegaly, the label states that the goal of treatment is to bring growth hormone and IGF-1 levels back to normal.1
What do human studies show?
In a randomized, double-blind, placebo-controlled trial in 204 people with advanced gastroenteropancreatic neuroendocrine tumors, disease progression or death occurred in 31.7% of the lanreotide group and 58.3% of the placebo group, a hazard ratio of 0.47, according to the label.1
In a 16-week trial in 115 people with carcinoid syndrome, the lanreotide group used rescue medicine on 34% of days compared with 49% for placebo. Differences in daily diarrhea and flushing were not statistically significant, according to the label.1
In a one-year acromegaly study of 108 people, 63% of those given lanreotide had a more than 50% drop in growth hormone during the 4-week placebo-controlled phase, compared with none on placebo, according to the label.1
What the evidence base contains
- Controlled human trial A randomized, double-blind, placebo-controlled trial in 204 people with advanced, well or moderately differentiated gastroenteropancreatic neuroendocrine tumors, with progression-free survival as the main outcome.1
- Controlled human trial A 16-week randomized, double-blind, placebo-controlled trial in 115 people with neuroendocrine tumors and carcinoid syndrome.1
- Controlled human trial A one-year acromegaly study in 108 people that began with a 4-week double-blind, placebo-controlled phase.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is lanreotide FDA-approved?
Yes. Drugs@FDA lists Somatuline Depot, application NDA022074, with an original approval date of August 30, 2007, a further lanreotide application (NDA215395) approved on December 17, 2021, and a generic application (ANDA217193) approved on May 21, 2024.2,3,4
The generic lanreotide label cited here (DailyMed SPL version 3, published June 2, 2025) states that it is indicated for long-term treatment of acromegaly when surgery or radiotherapy has not worked or is not an option, for adults with certain unresectable, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and for adults with carcinoid syndrome.1
The label has no boxed warning. It states that lanreotide is contraindicated in people with a history of allergic reactions to it.1
Its warnings cover gallstones and their complications, high or low blood sugar, slowing of the heart rate, thyroid function changes, and fatty stools from poor fat absorption.1
What is still unknown?
Whether lanreotide extends overall survival in neuroendocrine tumors: the label’s tumor trial measured progression-free survival.1
Whether it reduces diarrhea and flushing in carcinoid syndrome: the label reports these differences were not statistically significant.1
How the labels of other lanreotide products differ from the one cited here.1,2
Sources for this version
- 1Lanreotide acetate injection · SPL version 3 · published 2025-06-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026